Scholar Rock Holding Corporation has outlined its 2026 strategic priorities, focusing on advancing its anti-myostatin platform to address rare, severe neuromuscular diseases. The company’s main actions include seeking FDA and European Medicines Agency regulatory approvals and commercializing apitegromab for children and adults with spinal muscular atrophy $(SMA)$. Scholar Rock is building out its U.S. and European commercial organizations, including establishing a customer-facing team in the U.S. and initiating commercial operations in Europe, beginning with Germany. The company has also strengthened its leadership team to support its transition toward a commercial-stage organization and is advancing its pipeline of therapies targeting rare neuromuscular diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112295221) on January 12, 2026, and is solely responsible for the information contained therein.